Female doctor talking to older male patient
icon-tb-management
TB Management

TB & Biologics

Testing for TB is critical prior to biologic therapy

Treatment with biologic agents, in particular tumor necrosis factor-alpha (TNF-α) inhibitors, has revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. However, patients receiving anti-TNF-α therapy are at increased risk of tuberculosis (TB) infection. To reduce this risk, the WHO recommends latent TB infection (LTBI) testing in patients starting biologics (1).
QuantiFERON-TB Gold Plus tubes
The WHO recommends IGRA testing using QuantiFERON technology

QuantiFERON TB testing employs a simple blood test (IGRA) to aid in the detection of Mycobacterium tuberculosis infection. In its Global Tuberculosis Report 2020, the WHO concludes that its previously endorsed QuantiFERON-TB Gold Plus (QFT-Plus) test is one of only two commercially available IGRAs that may be used for testing latent TB infection (2).

QFT-Plus is a single visit TB test that is unaffected by BCG vaccination, features innovative CD8 T cell technology and offers >94% sensitivity and >97% specificity.

Before you initiate TNF-α inhibitor therapy, trust QFT-Plus for accurate TB detection
For more information, contact your QIAGEN sales representative.
Learn More

Contact us

References:
  1. World Health Organization. (2020) WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. https://apps.who.int/iris/bitstream/handle/10665/331170/9789240001503-eng.pdf
  2. World Health Organization. (2020) Global tuberculosis report. https://www.who.int/tb/data

QFT-Plus is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus Package Inserts, available in multiple languages, as well as up-to-date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.